Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-03-27
2007-03-27
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S320100, C435S455000, C536S023100, C536S023200, C536S023400, C536S023500
Reexamination Certificate
active
10463676
ABSTRACT:
The present invention relates to a method for treating cancer using p38/JTV-1 and a method for screening pharmaceutical composition for treating cancer. More particularly, this invention relates to the method for treating cancer, which comprises administering the effective amount of p38/JTV-1 protein or a nucleic acid encoding for said protein to the patient and the method for screening a pharmaceutical composition for treating cancer characterized by selecting a substance having an effect on the increase of the activity of the p38/JTV-1 protein and the intracellular level thereof.The method according to the invention can be effectively used to treat cancer through the mechanism of suppressing the proliferation of cancer cells by binding to FBP (FUSE-binding protein) and thereby promoting the ubiquitination of FBP to downregulate c-myc gene, which is a proto-oncogene, and the mechanism of promoting the apoptosis of cells by binding to PDK-1 (phosphoinositide-dependent protein) and thereby inhibiting the phosphorylation of AKT (serine/threonine kinase). Also, p38/JTV-1 can be used as a target for screening of new anticancer agents, by virtue of such regulation mechanisms of p38/JTV-1.
REFERENCES:
patent: 5843757 (1998-12-01), Vogelstein et al.
Peracchi, A., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Branch, A., Trends in Biochem. Sci., vol. 23, pp. 45-50 (1998).
Chirila, T.V. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
S.T. Crooke, Antisense Res. & Application, Chapter 1, pp. 1-50 (S. Crooke, Ed.) (Publ. by Springer-Verlag) (1998).
Quevillon, S. et al., “Macromolecular Assemblage of Aminoacyl-tRNA Synthetases: Identification of Protein-Protein Interactions and Characterization of a Core Protein,” J. Mol. Biol., 1999, pp. 183-195, vol. 285.
Kolodner, R.D. et al., “Eukaryotic DNA mismatch repair,” Curr. Opin. Gene. Dev., 1999, pp. 89-96, vol. 9.
Nicolaides, N.C. et al., “Analysis of the 5′ Region ofPMS2Reveals Heterogeneous Transcripts and a Novel Overlapping Gene,” Genomics, 1995, pp. 329-334, vol. 29.
Duncan, R. et al., “A sequence-specific, single-strand binding protein activates the far upstream element of c-mycand defines a new DNA-binding motif,” Genes and Development, 1994, pp. 465-480, vol. 8.
Avigan, M.I. et al., “A Far Upstream Element Stimulates c-mycExpression in Undifferentiated Leukemia Cells,” J. Biol. Chem., Oct. 25, 1990, pp. 18538-18545, vol. 265, No. 30.
Kulik, G. et al., “Antiapoptotic Signalling by the Insulin-Like Growth Factor I Receptor, Phosphatidylinositol 3-Kinase, and Akt,” Mol. Cell. Biol., Mar. 1997, pp. 1595-1606, vol. 17, No. 3.
Franke, T.F. et al., “P13K: Downstream AKTion Blocks Apoptosis,” Cell, 1997, pp. 435-437, vol. 188, No. 4.
Kauffmann-Zeh, A. et al., “Suppression of c-Myc-induced apoptosis by Ras signaling through PI(3)K and PKB,” Nature, Feb. 6, 1997, pp. 544-548, vol. 385.
Hemmings, B.A., “Akt Signalling—Linking Membrane Events to Life and Death Decisions,” Science, Jan. 31, 1997, pp. 628-630, vol. 275, No. 5300.
Stokoe, D. et al., “Dual Role of Phosphatidylinositol-3,4,5-triphosphate in the Activation of Protein Kinase B,” Jul. 25, 1997, pp. 567-570, vol. 277.
Stephens, L. et al., “Protein Kinase B Kinases That Mediate Phosphatidylinositol 3,4,5-Triphosphate-Dependent Activation of Protein Kinase B,” Jan. 30, 1998, pp. 710-714, vol. 279.
Park, S.G. et al., “Precursor of Pro-apoptotic Cytokine Modulates Aminoacylation Activity of tRNA Synthetase,” J. Biol. Chem., 1999, pp. 16673-16676, vol. 274, No. 24.
Wilson, J.M. et al., “Hepatocyte-directed Gene Transferin vivoLeads to Transient Improvement of Hypercholesterolemia in Low Density Lipoprotein Receptor-deficient Rabbits,” J. Biol. Chem., 1992, pp. 963-967, vol. 267, No. 2.
Wu, G.Y. et al., “Receptor-mediated Gene Delivery and Expressionin Vivo,” J. Biol. Chem., 1988, pp. 14621-14624, vol. 263, No. 29.
Miller, A.D., “Human gene therapy comes of age,” Nature, Jun. 11, 1992, pp. 455-460, vol. 357.
Rosenfeld, M.A. et al., “In VivoTransfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium,” Cell, Jan. 10, 1992, pp. 143-155, vol. 68.
Lemarchand, P. et al., “Adenovirus-mediated transfer of a recombinant human α1-antitrypsin cDNA to human endothelial cells,” Proc. Natl. Acad. Sci. USA, Jul. 1992, pp. 6482-6486, vol. 89.
Wolfe, J.H. et al., “Herpesvirus vector gene transfer and expression of β-glucuronidase in the central nervous system of MPS VII mice,” Nature Genetics, Aug. 1992, pp. 379-384, vol. 1.
Kang, J. et al., “Heat Shock Protein 90 Mediates Protein-protein Interactions between Human Aminoacyl-tRNA Synthetases,” J. Biol. Chem., Oct. 13, 2000, pp. 31682-31688, vol. 275, No. 41.
Kim Sung-hoon
Park Bum-Joon
Seoul National University Industry Foundation
Zara Jane
LandOfFree
Method for treating cancer using p38/JTV-1 and method for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating cancer using p38/JTV-1 and method for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating cancer using p38/JTV-1 and method for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3784447